Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

"Authorized" Generics Will Be Subject To "Best Price" Calculations, CMS Suggests

This article was originally published in The Pink Sheet Daily

Executive Summary

Letter to GPhA from agency says that the products are considered innovator multiple source drugs, which would discourage the use of the practice by brand firms. CMS says it is reviewing its policy on calculation of prices for such products.

You may also be interested in...



CMS Seeks List Of "Authorized" Generics For Use In "Best Price" Reporting, GPhA Says

The Generic Pharmaceutical Association anticipates the National Governors Association's updated Medicaid recommendations will endorse the inclusion of authorized generics in Medicaid "best price" reporting. CMS has indicated it will consider adding authorized generics to its calculations.

CMS Seeks List Of "Authorized" Generics For Use In "Best Price" Reporting, GPhA Says

The Generic Pharmaceutical Association anticipates the National Governors Association's updated Medicaid recommendations will endorse the inclusion of authorized generics in Medicaid "best price" reporting. CMS has indicated it will consider adding authorized generics to its calculations.

FTC Should Study Competitive Impact Of "Authorized" Generics, Senators Say

Bipartisan group of senators requests investigation of the short- and long-term competitive impacts of "authorized" generics. Formal study request and remarks by one of the commissioners suggest the generic industry's arguments against the practice are gaining traction on Capitol Hill and at FTC.

Topics

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel